Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6602684B1 · kind B1 · utility
550Cited by
9References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 20, 1999 |
| Grant date | Aug 5, 2003 |
| Priority date | — |
| Expiry date | Apr 20, 2019 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/802
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.